Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 4/2018

01-11-2018 | Case based reviews

The importance of standardisation of measurement and reference intervals for detection of phaeochromocytoma and paraganglioma (PPGL)

Authors: Tomás P. Griffin, Delia Bogdanet, Patrick Navin, Grace Callagy, Paula M. O’Shea, Marcia Bell

Published in: Irish Journal of Medical Science (1971 -) | Issue 4/2018

Login to get access

Abstract

A 51-year-old male presented 25 years ago with excessive sweating and haematuria. Blood pressure was labile. CT abdomen showed a large right-sided adrenal mass. Two 24-h urine collections showed elevated urinary catecholamines. Right adrenal resection was performed; a phaeochromocytoma (PC) was confirmed histologically. Two decades later, the patient represented with excessive sweating and measured variable blood pressure readings. Measurement of plasma metanephrines (PMets) showed elevated normetanephrine (NMN) [50,250 (R.I. 0-1180) pmol/L] and metanephrine (MN) [1030 (R.I. 0-510) pmol/L] values. CT abdomen showed a 100 × 90 × 63 mm enhancing mass in the right retroperitoneum. Curative resection was undertaken confirming recurrent PC. Follow-up post-resection, plasma NMN was discordant, 1314 pmol/L (above decision threshold) at 30 min and 911 pmol/L (below decision threshold) at 40 min. Acute clinical awareness of persistent disease mandated the performance of a metaiodobenzylguanidine (MIBG) scan and CT abdomen. These confirmed residual disease in the upper right side of the retroperitoneum. Persistent disease following redo surgery could have been missed if only seated-sampling upper reference limits were applied to PMets collected at 40 min. Our experience with this patient triggered a review of our PMets sampling strategy. There was no statistically significant difference in PMets sampled at 30 and at 40 min seated-rest. Optimum diagnostic test accuracy was achieved using a supine-sampling strategy at a single time point (30 min). Our case highlights the importance of maintaining a high index of clinical suspicion for residual/recurrent disease in the face of inconclusive biochemistry, followed by appropriate targeted radiology using MIBG or PET-CT in patients with PPGL.
Literature
2.
go back to reference Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT (1983) Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 58(12):802–804PubMed Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT (1983) Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 58(12):802–804PubMed
3.
go back to reference Stenstrom G, Svardsudd K (1986) Pheochromocytoma in Sweden 1958-1981. An analysis of the national cancer registry data. Acta Med Scand 220(3):225–232CrossRefPubMed Stenstrom G, Svardsudd K (1986) Pheochromocytoma in Sweden 1958-1981. An analysis of the national cancer registry data. Acta Med Scand 220(3):225–232CrossRefPubMed
4.
go back to reference Darr R, Pamporaki C, Peitzsch M et al (2014) Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol 80(4):478–486CrossRef Darr R, Pamporaki C, Peitzsch M et al (2014) Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol 80(4):478–486CrossRef
7.
go back to reference Lenders JW, Pacak K, Walther MM et al (2002) Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287(11):1427–1434CrossRefPubMed Lenders JW, Pacak K, Walther MM et al (2002) Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287(11):1427–1434CrossRefPubMed
8.
go back to reference Raber W, Raffesberg W, Bischof M et al (2000) Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 160(19):2957–2963CrossRefPubMed Raber W, Raffesberg W, Bischof M et al (2000) Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 160(19):2957–2963CrossRefPubMed
9.
10.
go back to reference Unger N, Pitt C, Schmidt IL et al (2006) Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 154(3):409–417CrossRefPubMed Unger N, Pitt C, Schmidt IL et al (2006) Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 154(3):409–417CrossRefPubMed
11.
go back to reference Giovanella L, Squin N, Ghelfo A, Ceriani L. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. Q J Nucl Med Mol Imaging 2006;50(4):344–347 Giovanella L, Squin N, Ghelfo A, Ceriani L. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. Q J Nucl Med Mol Imaging 2006;50(4):344–347
12.
go back to reference Vaclavik J, Stejskal D, Lacnak B et al (2007) Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens 25(7):1427–1431CrossRefPubMed Vaclavik J, Stejskal D, Lacnak B et al (2007) Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens 25(7):1427–1431CrossRefPubMed
15.
go back to reference Procopiou M, Finney H, Akker SA et al (2009) Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors. Eur J Endocrinol 161(1):131–140CrossRefPubMed Procopiou M, Finney H, Akker SA et al (2009) Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors. Eur J Endocrinol 161(1):131–140CrossRefPubMed
16.
go back to reference Grouzmann E, Drouard-Troalen L, Baudin E et al (2010) Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma. Eur J Endocrinol 162(5):951–960CrossRefPubMed Grouzmann E, Drouard-Troalen L, Baudin E et al (2010) Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma. Eur J Endocrinol 162(5):951–960CrossRefPubMed
18.
go back to reference Sarathi V, Pandit R, Jagtap V et al (2011) Performance of plasma fractionated free metanephrines by enzyme immunoassay in the diagnosis of pheochromocytoma and paraganglioma. Endocr Pract 17(5):759–765CrossRefPubMed Sarathi V, Pandit R, Jagtap V et al (2011) Performance of plasma fractionated free metanephrines by enzyme immunoassay in the diagnosis of pheochromocytoma and paraganglioma. Endocr Pract 17(5):759–765CrossRefPubMed
20.
go back to reference Unger N, Hinrichs J, Deutschbein T et al (2012) Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin a for the diagnosis of pheochromocytoma in patients with adrenal mass. Exp Clin Endocrinol Diabetes 120(08):494–500PubMed Unger N, Hinrichs J, Deutschbein T et al (2012) Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin a for the diagnosis of pheochromocytoma in patients with adrenal mass. Exp Clin Endocrinol Diabetes 120(08):494–500PubMed
21.
go back to reference Mullins F, O’Shea P, FitzGerald R, Tormey W (2011) Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal. Clin Chem Lab Med 50(1):105–110PubMed Mullins F, O’Shea P, FitzGerald R, Tormey W (2011) Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal. Clin Chem Lab Med 50(1):105–110PubMed
22.
go back to reference Griffin TP, Casey R, Wall D, Bell M, O'Shea PM (2016) Evaluating the optimum rest period prior to blood collection for fractionated plasma free metanephrines analysis. Pract Lab Med 5:39–46CrossRefPubMedCentralPubMed Griffin TP, Casey R, Wall D, Bell M, O'Shea PM (2016) Evaluating the optimum rest period prior to blood collection for fractionated plasma free metanephrines analysis. Pract Lab Med 5:39–46CrossRefPubMedCentralPubMed
24.
go back to reference Plouin PF, Amar L, Dekkers OM et al (2016) European society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol 174(5):G1–G10CrossRefPubMed Plouin PF, Amar L, Dekkers OM et al (2016) European society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol 174(5):G1–G10CrossRefPubMed
25.
go back to reference Rao D, Peitzsch M, Prejbisz A et al (2017) Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. Eur J Endocrinol 177(2):103–113CrossRefPubMedCentralPubMed Rao D, Peitzsch M, Prejbisz A et al (2017) Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. Eur J Endocrinol 177(2):103–113CrossRefPubMedCentralPubMed
27.
go back to reference d'Herbomez M, Gouze V, Huglo D et al (2001) Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma. J Nucl Med 42(7):993–997PubMed d'Herbomez M, Gouze V, Huglo D et al (2001) Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma. J Nucl Med 42(7):993–997PubMed
28.
go back to reference Casey R, Garrahy A, Tuthill A et al (2014) Universal genetic screening uncovers a novel presentation of an SDHAF2 mutation. J Clin Endocrinol Metab 99(7):E1392–E1396CrossRefPubMed Casey R, Garrahy A, Tuthill A et al (2014) Universal genetic screening uncovers a novel presentation of an SDHAF2 mutation. J Clin Endocrinol Metab 99(7):E1392–E1396CrossRefPubMed
Metadata
Title
The importance of standardisation of measurement and reference intervals for detection of phaeochromocytoma and paraganglioma (PPGL)
Authors
Tomás P. Griffin
Delia Bogdanet
Patrick Navin
Grace Callagy
Paula M. O’Shea
Marcia Bell
Publication date
01-11-2018
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 4/2018
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-018-1756-7

Other articles of this Issue 4/2018

Irish Journal of Medical Science (1971 -) 4/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine